November 9, 2021 -- Biotechnology company Arbor Biotechnologies recently raised $215 million in a series B financing round to move its lead programs for liver and central nervous system diseases to the clinic.
Arbor will continue to invest in its novel discovery engine to develop the next generation of gene editing technology, the company said in a release.
The round was led by Temasek, Ally Bridge Group, and TCG Crossover. Chen Yu, a managing partner at TCG Crossover, will join Arbor's board of directors.
To date, Arbor has raised over $300 million.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
